WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
Application Deadline: May 15, 2025, 5pm ET
Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4445
[post_author] => 4
[post_date] => 2024-06-10 15:37:44
[post_date_gmt] => 2024-06-10 19:37:44
[post_content] =>
Envisagenics, an AI-enabled biotechnology firm specializing in RNA splicing therapeutics, has announced the completion of its Series B funding round. This round included investments from existing supporters Third Kind Venture Capital, Empire State Development, and Red Cell Partners, as well as new strategic investor Bristol Myers Squibb, which has been collaborating with Envisagenics on oncology research since 2022.
Read more about Envisagenics Series B award here.
[post_title] => CFB Client Envisagenics Secures $25 Million Series B Funding to Advance RNA Splicing Therapeutics
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => envisagenics-secures-25-million-series-b-funding-to-advance-rna-splicing-therapeutics
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:32
[post_modified_gmt] => 2024-11-19 15:50:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4445
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3006
[post_author] => 3
[post_date] => 2018-08-03 20:11:09
[post_date_gmt] => 2018-08-03 20:11:09
[post_content] => Stony Brook University Happenings recently profiled the Center for Biotechnology's designation as on of eight national accelerators under the Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation and Ventures (DRIVe). Excerpt below, read the full article here.
Sepsis occurs when chemicals released into the bloodstream to fight an infection trigger inflammatory responses throughout the body. It’s dangerous and often deadly. According to the U.S. Department of Health and Human Services, more than 250,000 people die from sepsis each year, and it is a leading cause of hospitalization in the U.S.
What if a simple test could identify the onset of sepsis as soon as it occurs? Better yet, what if wearable technology was available to alert doctors about sepsis in a patient before they ever show symptoms?
This may be possible in the future thanks to Stony Brook University’s participation in the federal government’s new BARDA-DRIVe initiative.
[caption id="attachment_3007" align="alignleft" width="300"]
Stony Brook, NY; Stony Brook University: Center for Biotechnology's (CFB) Director of Operations Diane Fabel talks with Alyssa Tuthill, Instructional Support Associate/Biomedical Engineering Labs Manager while Graduate Research Assistant Vaughn Greene works with samples.[/caption]
The initiative, launched by the Division of Research, Innovation and Ventures (DRIVe), will be overseen by the Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA).
BARDA has selected Stony Brook’s Center for Biotechnology as one of eight national accelerators across the country to assist in scouting faculty innovators and businesses that are developing health security technology that meets the program’s goals. The initiative plans to focus first on sepsis and the early detection and diagnosis of infections that threaten national health. More goals will be identified over time.
“National health security is essential for optimum public health, enabling our society to thrive,” said Stony Brook University President Samuel L. Stanley Jr. President Stanley is a biomedical researcher who specializes in emerging infectious diseases. He also chairs the Innovation Committee for the Long Island Regional Economic Development Council.
“With a proven record of research, discovery, innovation and product-development in the biomedical sciences, Stony Brook’s Center for Biotechnology is poised to become an important contributor to the BARDA-DRIVe initiative,” he said. “I am certain that the Center will advance and accelerate research discovery, and strategically collaborate with biotech companies to find solutions to better manage sepsis and emerging national health issues.”
[post_title] => Center for Biotechnology Tapped for New Healthcare Security Innovation Program
[post_excerpt] => “With a proven record of research, discovery, innovation and product-development in the biomedical sciences, Stony Brook’s Center for Biotechnology is poised to become an important contributor to the BARDA-DRIVe initiative”
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => center-for-biotechnology-tapped-for-new-healthcare-security-innovation-program
[to_ping] =>
[pinged] =>
[post_modified] => 2018-08-20 14:50:32
[post_modified_gmt] => 2018-08-20 14:50:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3006
[menu_order] => 118
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4051
[post_author] => 4
[post_date] => 2023-03-16 14:01:07
[post_date_gmt] => 2023-03-16 14:01:07
[post_content] =>
The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies through our commercialization assistance program, Concept to Clinic: Commercializing Innovation Education (e-C3i). This program provides entrepreneurial education for investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The eC3i course is being offered to investigators with active (or in a No-Cost Extension through 9/23) NIH-funded research projects from participating Institutes and Centers.
All applications must be received no later than April 14th, 2023. Apply Today! Applications can be submitted to NIBIB-SBIR@mail.nih.gov. All NHLBI grantees are encouraged to contact us (nhlbi_sbir@mail.nih.gov) if you are interested in participating or have any questions about the application process. Learn more here.
[post_title] => NIH Grantees: Learn How to Commercialize Your Tech
[post_excerpt] => The NIH is providing an opportunity for grantees to participate in an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-ec3i-2023
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:34:34
[post_modified_gmt] => 2024-08-22 15:34:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4051
[menu_order] => 5
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
Application Deadline: May 15, 2025, 5pm ET
Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 265
[max_num_pages] => 89
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
